Gulf Coast TX
EpiEndo commences Phase 2a trial for EP395 in COPD patients
REYKJAVIK, Iceland--(BUSINESS WIRE)--Nov 14, 2022-- |!| Rosenberg
REYKJAVIK, Iceland--(BUSINESS WIRE)--Nov 14, 2022-- |!| Rosenberg